Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

Öz

Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was to compare the treatment efficacy of patients receiving neoadjuvant or adjuvant treatment in locally advanced bladder cancer. Material and Methods: We retrospectively included 107 bladder cancer patients from 6 centres who underwent radical cystectomy and received perioperative chemotherapy. Patients were divided into 2 categories: (i) neoadjuvant chemotherapy (n=54) and (ii) adjuvant chemotherapy (n=53). Results: Median follow-up was 31.6 months (95%CI 21.8-41.4). 30-month disease-free survival (DFS) was 58.9% in the whole group, 56.3% in neoadjuvant and 61.5% in adjuvant. 30-month DFS after neoadjuvant treatment was 70.1% in

Anahtar Kelimeler

• Bladder cancer
• neoadjuvant chemotherapy
• radical cystectomy
• adjuvant chemotherapy
• outcome analysis

Kas-İnvaziv mesane kanserinde neoadjuvan ve adjuvan kemoterapinin sağkalım üzerine etkinliği: Çok merkezli çalışma

Öz

Amaç: Kasa invaze mesane kanserinin tedavisinde yüksek metastaz riski nedeniyle sistemik tedavi önerilmektedir. Neoadjuvan veya adjuvan tedaviyi karşılaştıran yeterli çalışma olmaması nedeniyle bu çalışmada amacımız lokal ileri evre mesane kanserinde neoadjuvan veya adjuvan tedavi alan hastaların tedavi etkinliğini karşılaştırmaktır. Gereç ve Yöntemler: Radikal sistektomi yapılan ve perioperatif kemoterapi alan 6 merkezden 107 mesane kanseri hastası retrospektif olarak çalışmaya dahil edildi. Hastalar 2 kategoriye ayrıldı: (i) neoadjuvan kemoterapi (n=54) ve (ii) adjuvan kemoterapi (n=53). Ortanca takip süresi 31.6 aydı (%95CI 21.8-41.4). 30. ay hastalıksız sağkalım oranı (HSO) tüm grupta %58.9, neoadjuvanda %56.3 ve adjuvanda %61.5 idi. Neoadjuvan tedavi sonrası 30.ay HSS evrelemeye göre

Anahtar Kelimeler

• mesane kanseri
• neoadjuvan kemoterapi
• radikal sistektomi
• adjuvan kemoterapi
• sağkalım sonuçları

Kaynakça

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan 12;73(1):17–48.
2. Flaig TW, Spiess PE, Chair V, Abern M, Agarwal N, Buyyounouski MK, et al. NCCN Guidelines Version 3.2023 Bladder Cancer Rick Bangs, MBA ¥ Patient Advocate [Internet]. 2023. Available from: https://www.nccn.org/home/member-
3. Patel VG, Oh WK, Galsky MD. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 Sep 7;70(5):404–23.
4. Ripping TM, Rammant E, Witjes JA, Aaronson NK, van Hemelrijck M, van Hoogstraten LMC, et al. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. Health Qual Life Outcomes. 2022 Dec 29;20(1):171.
5. Takahashi K, Urabe F, Suhara Y, Nakano J, Yoshihara K, Goto Y, et al. Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study. Jpn J Clin Oncol. 2023 Dec 7;53(12):1208–14.
6. Leow JJ, Chang SL, Bellmunt J. Reply from Authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol 2014;66:55–6. Eur Urol. 2014 Jul;66(1):57–8.
7. Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, et al. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 May;1(1):83–90.
8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. New England Journal of Medicine. 2003 Aug 28;349(9):859–66.

9. Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. Journal of Clinical Oncology. 2022 Jun 20;40(18):2013–22.
10. Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, et al. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jan; 7(3):614-24.
11. Peyrottes A, Ouzaid I, Califano G, Hermieu JF, Xylinas E. Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. Medicina (B Aires). 2021 Jul 29;57(8):769.
12. Splinter TAW, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, et al. The Prognostic Value of the Pathological Response to Combination Chemotherapy before Cystectomy in Patients with Invasive Bladder Cancer. Journal of Urology. 1992 Mar;147(3 Part 1):606–8.
13. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly Wm, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology: Seminars and Original Investigations. 2014 Jul;32(5):637–44.
14. Narain TA, Tosh JM, Gautam G, Talwar HS, Panwar VK, Mittal A, et al. Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence. Urology. 2021 Aug; 154:8–15.
15. Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022 Aug;82(2):212–22.
16. Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. Clinical Cancer Research. 2022 Dec 1;28(23):5107–14.
17. Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, et al. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. Journal of Urology. 2021 Oct;206(4):924–32.
18. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):76–86.
19. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102-2114

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Onkoloji

Bölüm

Araştırma Makalesi

Yazarlar

Nargiz Majidova ^*
0000-0002-2575-5819
Türkiye

Ahmet Emin Öztürk
0000-0003-3365-5540
Türkiye

Rumeysa Çolak
0000-0002-3867-0793
Türkiye

Özge Yalıcı
0009-0002-0260-7511
Türkiye

Mehmet Cihan İçli
0000-0002-7857-6902
Türkiye

Barış Köksal
0000-0002-0418-5749
Türkiye

Murat Arcagök
0000-0002-4058-6929
Türkiye

Sevdenur Taşkın
0000-0002-3674-244X
Türkiye

Yaprak Caglar Bu kişi benim
0009-0006-4296-3405
Türkiye

Ali Kaan Güren
0000-0002-3562-5006
Türkiye

Erkam Kocaaslan
0000-0002-8994-2904
Türkiye

Pınar Erel
0000-0002-2797-2075
Türkiye

Yeşim Ağyol
0000-0002-4409-6003
Türkiye

Nadiye Sever
0000-0001-7312-3827
Türkiye

Abdussamet Çelebi
0000-0002-6922-1018
Türkiye

Rukiye Arıkan
0000-0003-2688-1515
Türkiye

Selver Işık
0000-0002-2726-1740
Türkiye

Vedat Bayoğlu
0000-0002-0481-1084
Türkiye

Osman Köstek
0000-0002-1901-5603
Türkiye

Erdoğan Selçuk Şeber
0000-0001-9081-2405
Türkiye

Zuhat Urakçı
0000-0003-3878-988X
Türkiye

Murat Sarı
0000-0003-0596-1559
Türkiye

Yayımlanma Tarihi

25 Mart 2025

Gönderilme Tarihi

29 Ekim 2024

Kabul Tarihi

6 Mart 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 16 Sayı: 1

DOI

https://doi.org/10.18663/tjcl.1575691

IZ

https://izlik.org/JA74AX42TF

Kaynak Göster

RIS / Bibtex

APA

Majidova, N., Öztürk, A. E., Çolak, R., Yalıcı, Ö., İçli, M. C., Köksal, B., Arcagök, M., Taşkın, S., Caglar, Y., Güren, A. K., Kocaaslan, E., Erel, P., Ağyol, Y., Sever, N., Çelebi, A., Arıkan, R., Işık, S., Bayoğlu, V., Köstek, O., … Sarı, M. (2025). Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. Turkish Journal of Clinics and Laboratory, 16(1), 123-130. https://doi.org/10.18663/tjcl.1575691

AMA

1.Majidova N, Öztürk AE, Çolak R, vd. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. TJCL. 2025;16(1):123-130. doi:10.18663/tjcl.1575691

Chicago

Majidova, Nargiz, Ahmet Emin Öztürk, Rumeysa Çolak, vd. 2025. “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”. Turkish Journal of Clinics and Laboratory 16 (1): 123-30. https://doi.org/10.18663/tjcl.1575691.

EndNote

Majidova N, Öztürk AE, Çolak R, Yalıcı Ö, İçli MC, Köksal B, Arcagök M, Taşkın S, Caglar Y, Güren AK, Kocaaslan E, Erel P, Ağyol Y, Sever N, Çelebi A, Arıkan R, Işık S, Bayoğlu V, Köstek O, Şeber ES, Urakçı Z, Sarı M (01 Mart 2025) Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. Turkish Journal of Clinics and Laboratory 16 1 123–130.

IEEE

[1]N. Majidova vd., “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”, TJCL, c. 16, sy 1, ss. 123–130, Mar. 2025, doi: 10.18663/tjcl.1575691.

ISNAD

Majidova, Nargiz - Öztürk, Ahmet Emin - Çolak, Rumeysa - Yalıcı, Özge - İçli, Mehmet Cihan - Köksal, Barış - Arcagök, Murat v.dğr. “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”. Turkish Journal of Clinics and Laboratory 16/1 (01 Mart 2025): 123-130. https://doi.org/10.18663/tjcl.1575691.

JAMA

1.Majidova N, Öztürk AE, Çolak R, Yalıcı Ö, İçli MC, Köksal B, Arcagök M, Taşkın S, Caglar Y, Güren AK, Kocaaslan E, Erel P, Ağyol Y, Sever N, Çelebi A, Arıkan R, Işık S, Bayoğlu V, Köstek O, Şeber ES, Urakçı Z, Sarı M. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. TJCL. 2025;16:123–130.

MLA

Majidova, Nargiz, vd. “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”. Turkish Journal of Clinics and Laboratory, c. 16, sy 1, Mart 2025, ss. 123-30, doi:10.18663/tjcl.1575691.

Vancouver

1.Nargiz Majidova, Ahmet Emin Öztürk, Rumeysa Çolak, Özge Yalıcı, Mehmet Cihan İçli, Barış Köksal, Murat Arcagök, Sevdenur Taşkın, Yaprak Caglar, Ali Kaan Güren, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Nadiye Sever, Abdussamet Çelebi, Rukiye Arıkan, Selver Işık, Vedat Bayoğlu, Osman Köstek, Erdoğan Selçuk Şeber, Zuhat Urakçı, Murat Sarı. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. TJCL. 01 Mart 2025;16(1):123-30. doi:10.18663/tjcl.1575691

Kas-İnvaziv mesane kanserinde neoadjuvan ve adjuvan kemoterapinin sağkalım üzerine etkinliği: Çok merkezli çalışma

Öz

Amaç: Kasa invaze mesane kanserinin tedavisinde yüksek metastaz riski nedeniyle sistemik tedavi önerilmektedir. Neoadjuvan veya adjuvan tedaviyi karşılaştıran yeterli çalışma olmaması nedeniyle bu çalışmada amacımız lokal ileri evre mesane kanserinde neoadjuvan veya adjuvan tedavi alan hastaların tedavi etkinliğini karşılaştırmaktır. Gereç ve Yöntemler: Radikal sistektomi yapılan ve perioperatif kemoterapi alan 6 merkezden 107 mesane kanseri hastası retrospektif olarak çalışmaya dahil edildi. Hastalar 2 kategoriye ayrıldı: (i) neoadjuvan kemoterapi (n=54) ve (ii) adjuvan kemoterapi (n=53). Ortanca takip süresi 31.6 aydı (%95CI 21.8-41.4). 30. ay hastalıksız sağkalım oranı (HSO) tüm grupta %58.9, neoadjuvanda %56.3 ve adjuvanda %61.5 idi. Neoadjuvan tedavi sonrası 30.ay HSS evrelemeye göre

Anahtar Kelimeler

• mesane kanseri
• neoadjuvan kemoterapi
• radikal sistektomi
• adjuvan kemoterapi
• sağkalım sonuçları

Kaynakça

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan 12;73(1):17–48.
2. Flaig TW, Spiess PE, Chair V, Abern M, Agarwal N, Buyyounouski MK, et al. NCCN Guidelines Version 3.2023 Bladder Cancer Rick Bangs, MBA ¥ Patient Advocate [Internet]. 2023. Available from: https://www.nccn.org/home/member-
3. Patel VG, Oh WK, Galsky MD. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 Sep 7;70(5):404–23.
4. Ripping TM, Rammant E, Witjes JA, Aaronson NK, van Hemelrijck M, van Hoogstraten LMC, et al. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. Health Qual Life Outcomes. 2022 Dec 29;20(1):171.
5. Takahashi K, Urabe F, Suhara Y, Nakano J, Yoshihara K, Goto Y, et al. Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study. Jpn J Clin Oncol. 2023 Dec 7;53(12):1208–14.
6. Leow JJ, Chang SL, Bellmunt J. Reply from Authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol 2014;66:55–6. Eur Urol. 2014 Jul;66(1):57–8.
7. Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, et al. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 May;1(1):83–90.
8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. New England Journal of Medicine. 2003 Aug 28;349(9):859–66.

9. Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. Journal of Clinical Oncology. 2022 Jun 20;40(18):2013–22.
10. Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, et al. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jan; 7(3):614-24.
11. Peyrottes A, Ouzaid I, Califano G, Hermieu JF, Xylinas E. Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. Medicina (B Aires). 2021 Jul 29;57(8):769.
12. Splinter TAW, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, et al. The Prognostic Value of the Pathological Response to Combination Chemotherapy before Cystectomy in Patients with Invasive Bladder Cancer. Journal of Urology. 1992 Mar;147(3 Part 1):606–8.
13. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly Wm, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology: Seminars and Original Investigations. 2014 Jul;32(5):637–44.
14. Narain TA, Tosh JM, Gautam G, Talwar HS, Panwar VK, Mittal A, et al. Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence. Urology. 2021 Aug; 154:8–15.
15. Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022 Aug;82(2):212–22.
16. Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. Clinical Cancer Research. 2022 Dec 1;28(23):5107–14.
17. Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, et al. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. Journal of Urology. 2021 Oct;206(4):924–32.
18. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):76–86.
19. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102-2114

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Onkoloji

Bölüm

Araştırma Makalesi

Yazarlar

Nargiz Majidova ^*
0000-0002-2575-5819
Türkiye

Ahmet Emin Öztürk
0000-0003-3365-5540
Türkiye

Rumeysa Çolak
0000-0002-3867-0793
Türkiye

Özge Yalıcı
0009-0002-0260-7511
Türkiye

Mehmet Cihan İçli
0000-0002-7857-6902
Türkiye

Barış Köksal
0000-0002-0418-5749
Türkiye

Murat Arcagök
0000-0002-4058-6929
Türkiye

Sevdenur Taşkın
0000-0002-3674-244X
Türkiye

Yaprak Caglar Bu kişi benim
0009-0006-4296-3405
Türkiye

Ali Kaan Güren
0000-0002-3562-5006
Türkiye

Erkam Kocaaslan
0000-0002-8994-2904
Türkiye

Pınar Erel
0000-0002-2797-2075
Türkiye

Yeşim Ağyol
0000-0002-4409-6003
Türkiye

Nadiye Sever
0000-0001-7312-3827
Türkiye

Abdussamet Çelebi
0000-0002-6922-1018
Türkiye

Rukiye Arıkan
0000-0003-2688-1515
Türkiye

Selver Işık
0000-0002-2726-1740
Türkiye

Vedat Bayoğlu
0000-0002-0481-1084
Türkiye

Osman Köstek
0000-0002-1901-5603
Türkiye

Erdoğan Selçuk Şeber
0000-0001-9081-2405
Türkiye

Zuhat Urakçı
0000-0003-3878-988X
Türkiye

Murat Sarı
0000-0003-0596-1559
Türkiye

Yayımlanma Tarihi

25 Mart 2025

Gönderilme Tarihi

29 Ekim 2024

Kabul Tarihi

6 Mart 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 16 Sayı: 1

DOI

https://doi.org/10.18663/tjcl.1575691

IZ

https://izlik.org/JA74AX42TF

Kaynak Göster

RIS / Bibtex

APA

Majidova, N., Öztürk, A. E., Çolak, R., Yalıcı, Ö., İçli, M. C., Köksal, B., Arcagök, M., Taşkın, S., Caglar, Y., Güren, A. K., Kocaaslan, E., Erel, P., Ağyol, Y., Sever, N., Çelebi, A., Arıkan, R., Işık, S., Bayoğlu, V., Köstek, O., … Sarı, M. (2025). Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. Turkish Journal of Clinics and Laboratory, 16(1), 123-130. https://doi.org/10.18663/tjcl.1575691

AMA

1.Majidova N, Öztürk AE, Çolak R, vd. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. TJCL. 2025;16(1):123-130. doi:10.18663/tjcl.1575691

Chicago

Majidova, Nargiz, Ahmet Emin Öztürk, Rumeysa Çolak, vd. 2025. “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”. Turkish Journal of Clinics and Laboratory 16 (1): 123-30. https://doi.org/10.18663/tjcl.1575691.

EndNote

Majidova N, Öztürk AE, Çolak R, Yalıcı Ö, İçli MC, Köksal B, Arcagök M, Taşkın S, Caglar Y, Güren AK, Kocaaslan E, Erel P, Ağyol Y, Sever N, Çelebi A, Arıkan R, Işık S, Bayoğlu V, Köstek O, Şeber ES, Urakçı Z, Sarı M (01 Mart 2025) Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. Turkish Journal of Clinics and Laboratory 16 1 123–130.

IEEE

[1]N. Majidova vd., “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”, TJCL, c. 16, sy 1, ss. 123–130, Mar. 2025, doi: 10.18663/tjcl.1575691.

ISNAD

Majidova, Nargiz - Öztürk, Ahmet Emin - Çolak, Rumeysa - Yalıcı, Özge - İçli, Mehmet Cihan - Köksal, Barış - Arcagök, Murat v.dğr. “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”. Turkish Journal of Clinics and Laboratory 16/1 (01 Mart 2025): 123-130. https://doi.org/10.18663/tjcl.1575691.

JAMA

1.Majidova N, Öztürk AE, Çolak R, Yalıcı Ö, İçli MC, Köksal B, Arcagök M, Taşkın S, Caglar Y, Güren AK, Kocaaslan E, Erel P, Ağyol Y, Sever N, Çelebi A, Arıkan R, Işık S, Bayoğlu V, Köstek O, Şeber ES, Urakçı Z, Sarı M. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. TJCL. 2025;16:123–130.

MLA

Majidova, Nargiz, vd. “Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study”. Turkish Journal of Clinics and Laboratory, c. 16, sy 1, Mart 2025, ss. 123-30, doi:10.18663/tjcl.1575691.

Vancouver

1.Nargiz Majidova, Ahmet Emin Öztürk, Rumeysa Çolak, Özge Yalıcı, Mehmet Cihan İçli, Barış Köksal, Murat Arcagök, Sevdenur Taşkın, Yaprak Caglar, Ali Kaan Güren, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Nadiye Sever, Abdussamet Çelebi, Rukiye Arıkan, Selver Işık, Vedat Bayoğlu, Osman Köstek, Erdoğan Selçuk Şeber, Zuhat Urakçı, Murat Sarı. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study. TJCL. 01 Mart 2025;16(1):123-30. doi:10.18663/tjcl.1575691

Kaynakça

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan 12;73(1):17–48.
2. Flaig TW, Spiess PE, Chair V, Abern M, Agarwal N, Buyyounouski MK, et al. NCCN Guidelines Version 3.2023 Bladder Cancer Rick Bangs, MBA ¥ Patient Advocate [Internet]. 2023. Available from: https://www.nccn.org/home/member-
3. Patel VG, Oh WK, Galsky MD. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 Sep 7;70(5):404–23.
4. Ripping TM, Rammant E, Witjes JA, Aaronson NK, van Hemelrijck M, van Hoogstraten LMC, et al. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. Health Qual Life Outcomes. 2022 Dec 29;20(1):171.
5. Takahashi K, Urabe F, Suhara Y, Nakano J, Yoshihara K, Goto Y, et al. Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study. Jpn J Clin Oncol. 2023 Dec 7;53(12):1208–14.
6. Leow JJ, Chang SL, Bellmunt J. Reply from Authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol 2014;66:55–6. Eur Urol. 2014 Jul;66(1):57–8.
7. Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, et al. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 May;1(1):83–90.
8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. New England Journal of Medicine. 2003 Aug 28;349(9):859–66.

9. Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. Journal of Clinical Oncology. 2022 Jun 20;40(18):2013–22.
10. Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, et al. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jan; 7(3):614-24.
11. Peyrottes A, Ouzaid I, Califano G, Hermieu JF, Xylinas E. Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. Medicina (B Aires). 2021 Jul 29;57(8):769.
12. Splinter TAW, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, et al. The Prognostic Value of the Pathological Response to Combination Chemotherapy before Cystectomy in Patients with Invasive Bladder Cancer. Journal of Urology. 1992 Mar;147(3 Part 1):606–8.
13. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly Wm, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology: Seminars and Original Investigations. 2014 Jul;32(5):637–44.
14. Narain TA, Tosh JM, Gautam G, Talwar HS, Panwar VK, Mittal A, et al. Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence. Urology. 2021 Aug; 154:8–15.
15. Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022 Aug;82(2):212–22.
16. Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. Clinical Cancer Research. 2022 Dec 1;28(23):5107–14.
17. Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, et al. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. Journal of Urology. 2021 Oct;206(4):924–32.
18. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):76–86.
19. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102-2114